Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAISING FULL YEAR OUTLOOK AND INNOVATION TARGET, IMPROVING YEAR-END NET LEVERAGE RATIO TARGET SECOND QUARTER 2025 FINANCIAL RESULTS: REVENUE OF $1,241 MILLION, AN INCREASE OF 5% YEAR-OVER-YEAR; 8% ORGANIC CONSTANT CURRENCY GROWTH REPORTED NET INCOME OF $11 MILLION, ADJUSTED NET INCOME OF $131 MILLION ADJUSTED EBITDA OF $238 MILLION; ADJUSTED EBITDA MARGIN OF 19.2% REPORTED EPS OF $0.02, ADJUSTED EPS OF $0.26 NET LEVERAGE RATIO OF 4.0X ADJUSTED EBITDA FULL YEAR 2025 GUIDANCE: RAISING REVENUE GUIDANCE TO $4,570 TO $4,620 MILLION; EXPECT ACCELERATING ORGANIC CONSTANT CURRENCY REVENUE GROWTH OF 5% TO 6% VS. 3% IN 2024 RAISING 2025 INNOVATION REVENUE TARGET BY $60 MILLION TO $720 TO $800 MILLION REPORTED NET LOSS OF $(38) TO $(14) MILLION, RAISING GUIDANCE FOR ADJUSTED EBITDA TO $850 TO $890 MILLION REPORTED LOSS PER SHARE OF $(0.08) TO $(0.03), RAISING GUIDANCE FOR ADJUSTED EPS TO $0.85 TO $0.91 OUTLOOK INCORPORATES CURRENT ESTIMATE FOR NET TARIFF IMPACT AND DYNAMIC LANDSCAPE, MORE THAN OFFSET BY A STRONG FIRST HALF PERFORMANCE AND FOREIGN EXCHANGE TAILWINDS TO REVENUE VERSUS PRIOR EXPECTATIONS INCREASING EXPECTED GROSS DEBTPAYDOWN RANGE TO $500 TO $550 MILLION IN 2025 2025 YEAR-END NET LEVERAGE RATIO TARGET IMPROVED TO 3.8X TO 4.1X, ENABLED BY YEAR-TO-DATE EXECUTION AND DISCIPLINED WORKING CAPITAL MANAGEMENT GREENFIELD, IND.

ELANCO ANIMAL HEALTH REPORTS SECOND QUARTER 2025 RESULTS

THE EUROPEAN COMMISSION'S APPROVAL OF ZENRELIA REINFORCES SAFETY AND EFFICACY AND FURTHER EXPANDS OPPORTUNITIES TO TREAT ITCHY DOGS AROUND THE WORLD LAUNCH TO BEGIN IMMEDIATELY WITH PRODUCT IN MARKET BEFORE THE END OF Q3 2025 GREENFIELD, IND. , JULY 24, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) ANNOUNCED TODAY THAT ZENRELIA (ILUNOCITINIB) HAS RECEIVED APPROVAL BY THE EUROPEAN COMMISSION.

ELANCO SECURES APPROVAL OF ZENRELIA (ILUNOCITINIB) IN THE EUROPEAN UNION (EU), LAUNCHING INNOVATIVE CANINE DERMATOLOGY TREATMENT FOR ITCHY DOGS

GREENFIELD, IND. , JULY 10, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL ANNOUNCE ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, AUGUST 7, 2025.

ELANCO CONFIRMS DATE AND CONFERENCE CALL FOR SECOND QUARTER 2025 FINANCIAL RESULTS ANNOUNCEMENT

TRUCAN ULTRA CIV IS THE ONLY  ML BIVALENT CANINE INFLUENZA VIRUS (CIV)VACCINE OFFERING BROAD PROTECTION AGAINST H3N2 AND H3N8. 100% VIRUS NEUTRALIZATION AGAINST 33 CURRENT FIELD ISOLATES.1 UNLIKE CURRENTLY AVAILABLE PRODUCTS, ONLYTRUCAN ULTRA CIV DEMONSTRATES ZERO LUNG LESIONS IN VACCINATED DOGS POST H3N2 CHALLENGE.2,3,4 TRUCAN ULTRA CIV COMPLETES ELANCO'S EXTENSIVE LINE OF TRU PORTFOLIO VACCINES.

ELANCO RECEIVES USDA APPROVAL FOR TRUCAN ULTRA CIV H3N2/H3N8 (CANINE INFLUENZA VACCINE) BRINGING TO MARKET A HIGH STANDARD OF RESPIRATORY PROTECTION

HIGHLIGHTS: NEURIZON THERAPEUTICS AND ELANCO ANIMAL HEALTHENTER INTO AN EXCLUSIVE GLOBAL LICENSING AGREEMENT PROVIDES WORLDWIDE RIGHTSFOR NEURIZON TO UTILISE ELANCO'S INTELLECTUAL PROPERTY, PROVIDING EXCLUSIVE ACCESS TO AN EXTENSIVE PACKAGE OF NON-CLINICAL STUDIES AND MANUFACTURING DATA AND OUTLINESKEY TERMS FOR A FUTURE SUPPLY AGREEMENT FOR GMP-COMPLIANT MONEPANTEL PROVIDES ACLEAR PATHWAY FOR ACCELERATED GLOBAL COMMERCIALISATIONOF NUZ-001 [1] AND SIGNIFICANTLYDE-RISKS FUTURE GLOBAL REGULATORY APPROVAL PROCESSES THE LICENSE AGREEMENT REPRESENTS THEFIRST STEP IN FORMALISING NEURIZON'S RELATIONSHIP WITH ELANCO, WITH THENEXT STEP FOCUSED ON FINALISING A SUPPLY AGREEMENT EXPECTED H2 CY 2025 MELBOURNE, AUSTRALIA , JULY 2, 2025 /PRNEWSWIRE/ -- NEURIZON THERAPEUTICS LIMITED (ASX: NUZ & NUZOA) ("NEURIZON" OR "THE COMPANY"), A CLINICAL-STAGE BIOTECH COMPANY DEDICATED TO ADVANCING INNOVATIVE TREATMENTS FOR NEURODEGENERATIVE DISEASES, IS PLEASED TO ANNOUNCE IT HAS EXECUTED AN EXCLUSIVEGLOBAL LICENSE AGREEMENTWITH ELANCO ANIMAL HEALTH INCORPORATED (ELANCO; NYSE: ELAN) AND AFFILIATESFOR MONEPANTEL, THE ACTIVE PHARMACEUTICAL INGREDIENT IN NUZ-001, NEURIZON'S LEAD INVESTIGATIONAL THERAPY IN DEVELOPMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES IN HUMANS. THIS LICENSE AGREEMENT REPRESENTS A CRITICAL INFLECTION POINT FOR NEURIZON, FURTHER STRENGTHENING THE COMPANY'S STRATEGIC OUTLOOK FOR THEDEVELOPMENT, MANUFACTURING AND POTENTIAL FUTURE COMMERCIALISATIONOF NUZ-001.

NEURIZON ENTERS INTO GLOBAL LICENSE WITH ELANCO TO ACCELERATE COMMERCIALISATION OF NUZ-001

GREENFIELD, IND. , JUNE 26, 2025 /PRNEWSWIRE/ --TODAY, ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) ANNOUNCED THE RELEASE OF ITS 2024 IMPACT REPORT, SHOWCASING ITS EFFORTS TO ENHANCE ANIMAL CARE, NOT JUST IMPROVING THE LIVES OF ANIMALS BUT ALSO THE PEOPLE WHO CARE FOR THEM.

ELANCO RELEASES 2024 IMPACT REPORT AND INTRODUCES NEW FRAMEWORK

COMPANY EXPECTS APPROVAL AND PRODUCT SUPPLY IN MARKET BEFORE THE END OF THIRD QUARTER GREENFIELD, IND. , JUNE 12, 2025 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) ANNOUNCED TODAY THAT ZENRELIA (ILUNOCITINIB) HAS BEEN GRANTED A POSITIVE OPINION BY THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP), PAVING THE WAY FOR THE PRODUCT'S MARKETING AUTHORIZATION IN THE EUROPEAN UNION IN THE NEXT 60 DAYS.

ELANCO RECEIVES POSITIVE OPINION ON ZENRELIA (ILUNOCITINIB) FROM EU'S COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

THE FIRST-OF-ITS-KIND REPORT INCLUDES RESULTS FROM MULTIPLE SURVEYS REVEALING JUST HOW BADLY DOGS AROUND THE COUNTRY ARE ITCHING FOR RELIEF. DATA REVEALS THAT NEARLY 9 IN 10 DOGS IN THE U.S. ARE "ITCHY DOGS" ACCORDING TO THEIR PET OWNERS, HAVING EXPERIENCED SYMPTOMS OF ITCHINESS AT SOME POINT IN THE YEAR.1 ALLERGY SEASON MAKES ITCH WORSE, WITH 83% OF PET OWNERS SAYING THAT INCREASED POLLEN LEVELS AFFECT THEIR DOG'S ITCH.1 VETERINARIANS ARE THE MOST TRUSTED ALLY IN SOLVING DOGS' ITCH, AND THE MAJORITY OF VETERINARIANS SAY THAT ITCHINESS IS THE MOST FRUSTRATING ISSUE THEY DEAL WITH.1 LEADING VETERINARIANS AND CANINE DERMATOLOGISTS, INCLUDING DRS.

ELANCO RELEASES NEW REPORT HIGHLIGHTING THE SIGNIFICANCE OF AMERICA'S ITCHY DOGS AND THE NEED FOR ITCH RELIEF

GREENFIELD, IND. , MAY 28, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THE APPOINTMENT OF ROBERT VANHIMBERGEN AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE JULY 7, 2025.

ELANCO APPOINTS ROBERT (BOB) VANHIMBERGEN AS CHIEF FINANCIAL OFFICER

GREENFIELD, IND. , MAY 16, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES.

Elanco Animal Health Incorporated

ELAN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Elanco Animal Health Incorporated

ELAN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ELAN